Structural variation in the glycogen synthase kinase 3β and brain‐derived neurotrophic factor genes in Japanese patients with bipolar disorders

Abstract Background Lithium is the first‐line drug for the treatment of bipolar disorders (BDs); however, not all patients responded. Glycogen synthase kinase (GSK) 3β and brain‐derived neurotrophic factor (BDNF) play a role in the therapeutic action of lithium. Since structural variations were repo...

Descripció completa

Dades bibliogràfiques

Autors principals:	Yosuke Suga, Keiichiro Yoshimoto, Shusuke Numata, Shinji Shimodera, Shogo Takamura, Naoto Kamimura, Ken Sawada, Hiromitsu Kazui, Tetsuro Ohmori, Shigeru Morinobu
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2020-03-01
Col·lecció:	Neuropsychopharmacology Reports
Matèries:	bipolar disorder brain‐derived neurotrophic factor copy number variation glycogen synthase kinase 3® lithium
Accés en línia:	https://doi.org/10.1002/npr2.12083
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!